



## ASX ANNOUNCEMENT

### Results of Annual General Meeting

**Sydney, 17 November 2023.** Actinogen Medical ASX: ACW (“ACW” or “the Company”) advises that its Annual General Meeting was held today at 10.00 am AEDT

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Resolutions 1 to 12 were passed on a poll, with Resolution 4 (Approval of increased 7.1A placement capacity), Resolution 11 (Approval to Amend Constitution – renewal of the Proportional Bid Provisions) and Resolution 12 (Approval to Amend Constitution – Employee share scheme provisions) being passed by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached.

**ENDS**

#### Investors

**Dr. Steven Gourlay**  
CEO & Managing Director  
P: +61 2 8964 7401  
E. [steven.gourlay@actinogen.com.au](mailto:steven.gourlay@actinogen.com.au)

**Michael Roberts**  
Investor Relations  
M: +61 423 866 231  
E. [michael.roberts@actinogen.com.au](mailto:michael.roberts@actinogen.com.au)

***Announcement authorised by the Board of Directors of Actinogen Medical***

#### About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

Actinogen is currently developing its lead compound, Xanamem,<sup>®</sup> as a promising new therapy for Alzheimer’s Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive

<sup>®</sup> Xanamem is a registered trademark of Actinogen Medical Limited

dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

### **Current and Upcoming Clinical Trials**

The **XanaCIDD Phase 2a depression trial** is a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 160 patients. Patients are evenly randomized to receive Xanamem 10 mg once daily or placebo, in some cases in addition to their existing antidepressant therapy, and effects on cognition and depression are assessed.

The **XanaMIA Phase 2b Alzheimer's disease trial** is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and effects on cognition, function and progression of Alzheimer's disease are assessed. Thus, Xanamem is being assessed in this trial for its potential effects as both a cognitive enhancer and a disease course modifier.

### **About Xanamem**

Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11 $\beta$ -HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials.

The Company has studied 11 $\beta$ -HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in functional and cognitive ability in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem<sup>®</sup> is a trademark of Actinogen Medical.

**ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.**

# Disclosure of Proxy Votes

## Actinogen Medical Limited

Annual General Meeting

Friday, 17 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	576,529,298	565,381,238 98.07%	2,862,999 0.50%	609,412	8,285,061 1.44%	597,332,895 99.52%	2,862,999 0.48%	609,412	-
2 Re-election of Dr George Morstyn	P	673,860,043	662,177,707 98.27%	1,458,321 0.22%	614,376	10,224,015 1.52%	702,472,387 99.79%	1,458,321 0.21%	3,936,209	Passed
3 Election of Dr Nicki Vasquez	P	673,860,043	662,512,707 98.32%	1,123,321 0.17%	614,376	10,224,015 1.52%	706,129,220 99.84%	1,123,321 0.16%	614,376	Passed
4 Approval of increased 7.1A placement capacity	P	674,008,043	661,118,074 98.09%	2,665,954 0.40%	466,376	10,224,015 1.52%	704,734,587 99.62%	2,665,954 0.38%	466,376	Passed
5 Approval of Employee Share Loan Plan	P	560,879,430	541,501,498 96.55%	9,045,877 1.61%	3,403,105	10,332,055 1.84%	572,736,404 98.45%	9,045,877 1.55%	5,267,059	Passed
6 Approval of Employee Share Loan Plan Shares issue to Dr Steven Gourlay	P	578,650,220	558,417,902 96.50%	9,900,263 1.71%	75,197,919	10,332,055 1.79%	594,733,073 98.36%	9,900,263 1.64%	77,061,873	Passed
7 Approval of Employee Share Loan Plan Shares issue to Mr Malcolm McComas	P	578,650,220	501,685,218 86.70%	66,632,947 11.52%	3,403,105	10,332,055 1.79%	538,000,389 88.98%	66,632,947 11.02%	5,267,059	Passed
8 Approval of Employee Share Loan Plan Shares issue to Dr Geoffrey Brooke	P	578,650,220	558,417,902 96.50%	9,900,263 1.71%	3,403,105	10,332,055 1.79%	594,733,073 98.36%	9,900,263 1.64%	5,267,059	Passed



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of Employee Share Loan Plan Shares issue to Dr George Morstyn	P	578,650,220	558,417,902 96.50%	9,900,263 1.71%	3,403,105	10,332,055 1.79%	594,733,073 98.36%	9,900,263 1.64%	8,588,892	Passed
10 Approval of Employee Share Loan Plan Shares issue to Dr Nicki Vasquez	P	578,600,220	558,454,510 96.52%	9,863,655 1.70%	3,453,105	10,282,055 1.78%	594,719,681 98.37%	9,863,655 1.63%	5,317,059	Passed
11 Approval to Amend Constitution - renewal of the Proportional Bid Provisions	P	673,776,043	661,151,756 98.13%	2,444,772 0.36%	698,376	10,179,515 1.51%	704,723,769 99.65%	2,444,772 0.35%	698,376	Passed
12 Approval to Amend Constitution - Employee share scheme provisions	P	670,658,223	651,809,475 97.19%	8,674,733 1.29%	3,816,196	10,174,015 1.52%	695,375,988 98.77%	8,674,733 1.23%	3,816,196	Passed

